NPC Clinical Trial
Official title:
The Phase Ib/II, Open-label, Multicenter Study of IBI310 (Anti-CTLA4 mAb) in Combination With Sintilimab in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma That Failed Prior Anti-PD-1/PD-L1 Therapy
This is a phase 1b/II, open label, multicenter study of IBI310 (Anti-CTLA4 mAb) in combination with Sintilimab in patients with recurrent/metastatic Nasopharyngeal Carcinoma that failed prior Anti-PD-1/PD-L1 therapy
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03352778 -
IMRT vs 2DRT for NPC Patients
|
||
Active, not recruiting |
NCT03734809 -
NEO-SPACE Trial: Pembrolizumab and Chemoradiation in Nasopharyngeal Cancer
|
Phase 2 | |
Recruiting |
NCT03158324 -
Phase IIa Dose-Expansion and Biomarker Study of OPB-111077
|
Phase 2 | |
Recruiting |
NCT03919552 -
Cisplatin-based and Carboplatin-based Chemoradiation in Locoregionally Advanced Nasopharyngeal Carcinoma
|
Phase 3 | |
Not yet recruiting |
NCT04284332 -
Phase II Prospective Study of Bintrafusp Alfa in Previously Treated Patients With Recurrent and Metastatic (R/M) Non-keratinizing Nasopharyngeal Carcinoma (NPC)
|
Phase 2 | |
Recruiting |
NCT05983432 -
Study to Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
|
Phase 1 | |
Completed |
NCT03973723 -
Plasma EBV DNA Monitoring in Post-treatment NPC Patients
|
||
Active, not recruiting |
NCT01744587 -
Epstein-Barr Virus Reactivation and the Effect of EGCG on Virus Reactivation in Remission Patients
|
N/A |